Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,457,105

« Back to Dashboard

Summary for Patent: 5,457,105

Title: Quinazoline derivatives useful for treatment of neoplastic disease
Abstract:The invention concerns quinazoline derivatives of the formula I ##STR1## wherein m is 1, 2 or 3 and each R.sup.1 includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy; n is 1 or 2 and each R.sup.2 includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.
Inventor(s): Barker; Andrew J. (Macclesfield, GB2)
Assignee: Zeneca Limited (London, GB2)
Application Number:08/284,293
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,457,105

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9201095Jan 20, 1992
United Kingdom9213572Jun 26, 1992
United Kingdom9223735Nov 12, 1992

International Patent Family for Patent: 5,457,105

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria130000<disabled in preview>
Australia3101093<disabled in preview>
Australia661533<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?